What's Happening?
Astorg, a pan-European private equity firm, has completed the acquisition of the global microbiology business from Thermo Fisher Scientific. This acquisition establishes the business as an independent company, which will operate under a new brand later
in 2026. The microbiology business provides diagnostic consumables and equipment for microbiological testing across clinical, food safety, and pharmaceutical applications. Dirk Bontridder has been appointed as the CEO to lead the company through its next growth phase. The business serves over 15,000 customers in more than 100 countries and employs approximately 2,400 people.
Why It's Important?
This acquisition reflects Astorg's strategic focus on healthcare and its approach to complex transactions. By establishing the microbiology business as an independent entity, Astorg aims to enhance its global position in the diagnostics market. The move is significant for the healthcare industry as it could lead to increased innovation and competition in the microbiology diagnostics sector. The business's independence allows for more focused growth and development, potentially leading to advancements in diagnostic technologies and services.
What's Next?
Under Dirk Bontridder's leadership, the company will focus on accelerating innovation and strengthening its global market position. The introduction of a new corporate brand later in 2026 will mark a new chapter for the business. Astorg plans to leverage its expertise in healthcare to drive the company's growth and operational value creation. The success of this acquisition could influence future investments and acquisitions in the healthcare diagnostics sector.
